



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	75.39
Trade Time:	2:19 PM ET May 21, 2018
Change:	-2.98 (3.802%)
Day Range	74.85 - 78.85
52-Week Range	78.35 - 147.17
Volume	12,918,888

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup>, ISTODAX<sup>®</sup> and IDHIFA<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 16, 2018*  
[Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology \(ASCO\) Scientific Sessions](#)
- May 14, 2018*  
[Celgene Corporation to Webcast at Upcoming Investor Conferences and Events](#)
- May 4, 2018*  
[Celgene Reports First Quarter 2018 Operating and Financial Results](#)
- Apr 30, 2018*  
[Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs](#)
- Apr 24, 2018*  
[New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting](#)

## Upcoming Events [\[ View all \]](#)

- May 24, 2018 1:30 PM ET*  
[R&D Deep Dive on Multiple Myeloma](#)
- May 30, 2018 3:00 PM ET*  
[Bernstein Thirty-Fourth Annual Strategic Decisions Conference 2018](#)
- Feb 7, 2018*  
[Annual Report \(10-K\)](#)
- Apr 30, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2018*  
[Quarterly Report \(10-Q\)](#)
- Oct 26, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)

## Financials [\[ View all \]](#)